You are here

Adjunctive Use of Apyrase to Fibrinolytic Therapy

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL095169-01A1
Agency Tracking Number: HL095169
Amount: $226,120.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2009-2
Timeline
Solicitation Year: 2009
Award Year: 2009
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
APT THERAPEUTICS, INC. 893 NORTH WARSON ROAD
SAINT LOUIS, MO 63141
United States
DUNS: 192266141
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 RIDONG CHEN
 (314) 608-6932
 RCHEN@NIDUSCENTER.COM
Business Contact
 RIDONG CHEN
Phone: (314) 812-8054
Email: rchen@niduscenter.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for treatment of acute myocardial infarction. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. Using a protein informatics approach, we have successfully engineered human apyrases which exhibit both antiplatelet and anti-inflammatory activities. With the Phase I grant support, we will determine whether optimized human apyrases, in combination with tPA, induce rapid and sustained coronary artery recanalization without increasing bleeding risk. PUBLIC HEALTH RELEVANCE: We will utilize a coronary thrombotic model in dogs to validate whether human apyrase more effectively improve coronary patency than clopidogrel without increasing bleeding risk.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government